Physician profile
Beth A Goldman
NPI 1932225695
$1,342.10
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $199 · 2021: $448 · 2022: $52.78 · 2024: $80.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $64.99 · Food and Beverage: $15.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $64.99 |
| Food and Beverage | $15.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $214.55 | 2019-2022 | |
| Esperion Therapeutics, INC. | $93.21 | 2020-2021 | |
| Abbvie INC. | $91.74 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.99 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $66.44 | 2019 | |
| Astellas Pharma US INC | $64.99 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $57.25 | 2020-2021 | |
| Pfizer INC. | $54.37 | 2019 | |
| Glaxosmithkline, LLC. | $48.41 | 2019-2021 | |
| Sobi, INC | $42.19 | 2019 | |
| Amgen INC. | $41.18 | 2019 | |
| Lilly USA, LLC | $40.60 | 2021 | |
| Genentech USA, INC. | $38.97 | 2021 | |
| Mylan Specialty L.P. | $38.32 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $37.99 | 2019-2021 | |
| Allergan, INC. | $37.95 | 2020 | |
| Amarin Pharma, INC. | $33.69 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $32.59 | 2019 | |
| Alnylam Pharmaceuticals INC. | $27.68 | 2021 | |
| Horizon Therapeutics Plc | $24.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.21 | 2022 | |
| Daiichi Sankyo INC. | $15.09 | 2024 | Enhertu |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2020 | |
| Ethicon US, LLC | $12.95 | 2019 | |
| Optos, INC. | $12.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.